Lupin’s ProAir Rival Has 'Moved Ahead' Despite CRL
Lupin is staring at stretched launch timelines in the US for its generic ProAir following a Complete Response Letter, but the company maintains that its application has progressed and the market opportunity for the product remains attractive.
You may also be interested in...
Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.
Lupin managing director tells Scrip that manufacturing competence will be a “big advantage” in the biosimilars space, and also believes that the US albuterol market remains “very lucrative” despite the entry of authorized generics.
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.